Blockade of specific NOTCH ligands: a new promising approach in cancer therapy

Anaïs Briot; M Luisa Iruela-Arispe

doi:10.1158/2159-8290.CD-14-1501

Blockade of specific NOTCH ligands: a new promising approach in cancer therapy

Cancer Discov. 2015 Feb;5(2):112-4. doi: 10.1158/2159-8290.CD-14-1501.

Authors

Anaïs Briot¹, M Luisa Iruela-Arispe²

Affiliations

¹ Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
² Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, California. Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. arispe@mcdb.ucla.edu.

Abstract

The signaling specificity conveyed by distinct combination of NOTCH receptors/ligands has remained elusive. In this issue of Cancer Discovery, through the development of ligand-specific NOTCH inhibitors, Kangsamaksin and colleagues uncovered unique signaling outcomes downstream of DLL- and JAG-receptor activation and demonstrated their effects in the suppression of tumor angiogenesis.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Animals
Female
Humans
Immunoglobulin Fc Fragments / administration & dosage*
Intercellular Signaling Peptides and Proteins / metabolism*
Neoplasms / blood supply*
Neoplasms / therapy*
Receptor, Notch1 / administration & dosage*
Receptors, Notch / antagonists & inhibitors*
Recombinant Fusion Proteins / administration & dosage*

Substances

Immunoglobulin Fc Fragments
Intercellular Signaling Peptides and Proteins
Receptor, Notch1
Receptors, Notch
Recombinant Fusion Proteins

Grants and funding

R01 HL114086/HL/NHLBI NIH HHS/United States